DK0797452T3 - Modulering af immunreaktionen - Google Patents

Modulering af immunreaktionen

Info

Publication number
DK0797452T3
DK0797452T3 DK95939341T DK95939341T DK0797452T3 DK 0797452 T3 DK0797452 T3 DK 0797452T3 DK 95939341 T DK95939341 T DK 95939341T DK 95939341 T DK95939341 T DK 95939341T DK 0797452 T3 DK0797452 T3 DK 0797452T3
Authority
DK
Denmark
Prior art keywords
molecules
immunogen
administration
immune response
ligands
Prior art date
Application number
DK95939341T
Other languages
Danish (da)
English (en)
Inventor
Douglas Thomas Fearon
Paul Walter Dempsey
Original Assignee
Univ Cambridge Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cambridge Tech filed Critical Univ Cambridge Tech
Application granted granted Critical
Publication of DK0797452T3 publication Critical patent/DK0797452T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Optical Communication System (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95939341T 1994-12-06 1995-12-06 Modulering af immunreaktionen DK0797452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424631A GB9424631D0 (en) 1994-12-06 1994-12-06 Modulating the immune response
PCT/GB1995/002851 WO1996017625A1 (fr) 1994-12-06 1995-12-06 Modulation de la reponse immune

Publications (1)

Publication Number Publication Date
DK0797452T3 true DK0797452T3 (da) 2002-08-19

Family

ID=10765518

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95939341T DK0797452T3 (da) 1994-12-06 1995-12-06 Modulering af immunreaktionen

Country Status (12)

Country Link
US (2) US6238670B1 (fr)
EP (1) EP0797452B1 (fr)
JP (1) JPH10509723A (fr)
AT (1) ATE216593T1 (fr)
AU (1) AU709990B2 (fr)
CA (1) CA2207000A1 (fr)
DE (1) DE69526521T2 (fr)
DK (1) DK0797452T3 (fr)
ES (1) ES2176347T3 (fr)
GB (1) GB9424631D0 (fr)
PT (1) PT797452E (fr)
WO (1) WO1996017625A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
CA2297786C (fr) * 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouvel antigene immunoprotecteur contre la grippe a et son utilisation dans la vaccination
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
GB9727512D0 (en) * 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
WO1999064603A2 (fr) * 1998-06-12 1999-12-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine AUGMENTATION DE L'ACTIVATION DES CELLULES B ET DE LA SECRETION D'IMMUNOGLOBULINE PAR CO-STIMULATION DE RECEPTEURS DE L'ANTIGENE ET D'EBV Gp350/220
US20050244954A1 (en) * 1998-06-23 2005-11-03 Blackburn Gary F Binding acceleration techniques for the detection of analytes
EP1001021B1 (fr) 1998-09-25 2003-08-27 Wolfgang Prodinger Anticorps monoclonal contre le CD21 humain et son utilisation
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
WO2001092295A2 (fr) * 2000-05-30 2001-12-06 University Of Toronto Ligands pour cd21 et compositions associees destinees a moduler des reponses immunes
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
WO2002092011A2 (fr) * 2001-05-17 2002-11-21 La Jolla Pharmaceutical Company Methodes de traitement de pathologies a mediation anticorps utilisant des agents inhibant cd21
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
JP2006505252A (ja) * 2002-08-14 2006-02-16 アヴィディス エスアー 抗原およびアジュバントの多量体複合体
JP2004222435A (ja) * 2003-01-16 2004-08-05 Fuji Heavy Ind Ltd 電気自動車の駆動装置
US9475853B2 (en) 2012-01-19 2016-10-25 Albany Medical College Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
EP2827889A1 (fr) 2012-03-19 2015-01-28 Deutsches Krebsforschungszentrum Protéines de liaison du complexe du récepteur des lymphocytes b contenant des épitopes de lymphocytes t
EP2674168A1 (fr) * 2012-06-14 2013-12-18 PLS-Design GmbH Modulation des réponses des lymphocytes T d'effecteur par déplétion locale du composant complément C3
WO2014006063A2 (fr) 2012-07-02 2014-01-09 Medizinische Universität Wien Produit de séparation du complément c4d pour le traitement d'affections inflammatoires
US20200262879A1 (en) 2017-09-11 2020-08-20 Insideoutbio, Inc. Methods and compositions to enhance the immunogenicity of tumors
US20210403519A1 (en) 2018-11-02 2021-12-30 Insideoutbio, Inc. Methods and compositions to induce or suppress immune responses through the use of membrane bound complement split products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2023779A1 (fr) * 1989-08-23 1991-02-24 Margaret D. Moore Composes et methodes pour la detection et le traitement des infections a virus epstein-barr et des troubles de l'immunite
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
AU7566991A (en) * 1990-03-14 1991-10-10 Biomembrane Institute, The Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
ES2053413T3 (es) * 1992-05-14 1997-11-16 Polymun Scient Immunbio Forsch Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.

Also Published As

Publication number Publication date
PT797452E (pt) 2002-10-31
EP0797452B1 (fr) 2002-04-24
CA2207000A1 (fr) 1996-06-13
ATE216593T1 (de) 2002-05-15
DE69526521D1 (de) 2002-05-29
GB9424631D0 (en) 1995-01-25
JPH10509723A (ja) 1998-09-22
DE69526521T2 (de) 2002-12-05
EP0797452A1 (fr) 1997-10-01
US6238670B1 (en) 2001-05-29
WO1996017625A1 (fr) 1996-06-13
AU4120496A (en) 1996-06-26
US6891027B2 (en) 2005-05-10
AU709990B2 (en) 1999-09-09
US20020102656A1 (en) 2002-08-01
ES2176347T3 (es) 2002-12-01

Similar Documents

Publication Publication Date Title
DK0797452T3 (da) Modulering af immunreaktionen
DK338587D0 (da) Modulsamling af antistofgener, antistoffer fremstillet derved samt anvendelse deraf
DE68924850T2 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
ATE47155T1 (de) Monoklonaler antikoerper.
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
ES2181734T3 (es) Ensayo inmunologico de ciclosporina.
RU93058563A (ru) Полипептиды, иммунореагент, способ определения антител, способ индукции иммунного ответа, композиции, способ получения полипептида
IE811595L (en) Synthetic peptide antigens
NO20003716L (no) Protein D for anvendelse in vitro, renset antistoff som binder proteinet, samt anvendelser derav
ATE87655T1 (de) Markierer der t-zelle aktivierung.
AU3900589A (en) Antigenic constructs of major histocompatibility complex class 1 antigens with specific carrier molecules, the preparation and use thereof
FI20021626A (fi) Immuunimäärityksen reagenssi ja menetelmä hepatiitti C-viruksen (HCV) vasta-aineiden havaitsemiseksi
SE9103183D0 (sv) Virus-antibody complex
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
WO1998025958A3 (fr) Antigenes de surface de cellules de mammiferes
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
IT8720842A0 (it) Analisi immunologiva stratificata impiegando anticorpi legati a particelle di trasporto per determinare la presenza di un antigene.
ATE74662T1 (de) Immunoanalysetestverfahren fuer cholesterolepoxide.
EP0363109A3 (fr) Détermination d'un antigène de chlamydia ou de gonocoque en utilisant un support chargé positivement pour liaison ionique
EP0248534A3 (fr) Méthode pour détecter une infection provoquée par le virus SIDA
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DE69133185D1 (de) Entwicklung von dns-sonden und immunologischen reagenzien von menschlichen tumor-assoziierten antigenen
DK426588D0 (da) Fremgangsmaade til paavisning af celleoverfladeantigen
ATE87941T1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
DE3888437T2 (de) Immobilisierte Antikörper.